DK1317264T3 - Kombination af liponsyre og konjuensyrer til behandling af diabetiske forstyrrelser - Google Patents

Kombination af liponsyre og konjuensyrer til behandling af diabetiske forstyrrelser

Info

Publication number
DK1317264T3
DK1317264T3 DK01963002T DK01963002T DK1317264T3 DK 1317264 T3 DK1317264 T3 DK 1317264T3 DK 01963002 T DK01963002 T DK 01963002T DK 01963002 T DK01963002 T DK 01963002T DK 1317264 T3 DK1317264 T3 DK 1317264T3
Authority
DK
Denmark
Prior art keywords
treatment
combination
lipoic acid
conjuic
acids
Prior art date
Application number
DK01963002T
Other languages
Danish (da)
English (en)
Inventor
Oliver Hasselwander
Kai-Uwe Baldenius
Klaus Kraemer
Martin Jochen Klatt
Loni Schweikert
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Application granted granted Critical
Publication of DK1317264T3 publication Critical patent/DK1317264T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01963002T 2000-09-12 2001-09-11 Kombination af liponsyre og konjuensyrer til behandling af diabetiske forstyrrelser DK1317264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045059A DE10045059A1 (de) 2000-09-12 2000-09-12 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
PCT/EP2001/010501 WO2002022111A2 (de) 2000-09-12 2001-09-11 Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen

Publications (1)

Publication Number Publication Date
DK1317264T3 true DK1317264T3 (da) 2004-11-29

Family

ID=7655916

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01963002T DK1317264T3 (da) 2000-09-12 2001-09-11 Kombination af liponsyre og konjuensyrer til behandling af diabetiske forstyrrelser

Country Status (10)

Country Link
US (1) US20030187058A1 (enExample)
EP (1) EP1317264B1 (enExample)
JP (1) JP2004508399A (enExample)
CN (1) CN1216602C (enExample)
AT (1) ATE271866T1 (enExample)
AU (1) AU2001284057A1 (enExample)
DE (2) DE10045059A1 (enExample)
DK (1) DK1317264T3 (enExample)
ES (1) ES2225593T3 (enExample)
WO (1) WO2002022111A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8795706B2 (en) * 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
DE602004014716D1 (de) * 2004-03-06 2008-08-14 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
JP4556061B2 (ja) * 2006-07-27 2010-10-06 ビーエイチエヌ株式会社 ヒアルロン酸産生増強剤
WO2008067403A2 (en) * 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
CN101396357B (zh) * 2007-09-29 2010-12-29 中国科学院上海生命科学研究院 硫辛酰胺在防治胰岛素抵抗中的用途
WO2009111635A2 (en) * 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
ES2579173T3 (es) 2009-06-15 2016-08-05 Encore Health, Llc Ésteres de colina para tratar presbicia y cataratas
CN101671331B (zh) * 2009-09-29 2011-06-01 寿光富康制药有限公司 硫辛酰维格列汀及其制备方法与应用
JP5245061B2 (ja) * 2010-05-12 2013-07-24 ビーエイチエヌ株式会社 経口用老化防止剤及び美容方法
AU2014321711B2 (en) 2013-09-19 2019-11-14 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
BR112016020181A8 (pt) 2014-03-03 2021-06-29 Encore Vision Inc composições de ácido lipoico éster colina e métodos de uso.
AU2016243516A1 (en) 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
DE69832520T2 (de) * 1997-12-12 2006-08-10 Purdue Research Foundation, West Lafayette Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US20020025310A1 (en) * 2000-02-02 2002-02-28 Bland Jeffrey S. Compositions and methods for promoting healthy joints

Also Published As

Publication number Publication date
ES2225593T3 (es) 2005-03-16
JP2004508399A (ja) 2004-03-18
DE10045059A1 (de) 2002-03-21
EP1317264A2 (de) 2003-06-11
ATE271866T1 (de) 2004-08-15
AU2001284057A1 (en) 2002-03-26
EP1317264B1 (de) 2004-07-28
CN1455670A (zh) 2003-11-12
CN1216602C (zh) 2005-08-31
US20030187058A1 (en) 2003-10-02
DE50103029D1 (de) 2004-09-02
WO2002022111A3 (de) 2003-02-27
WO2002022111A2 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
DK1317264T3 (da) Kombination af liponsyre og konjuensyrer til behandling af diabetiske forstyrrelser
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
IL154710A0 (en) Isoxazole derivatives and pharmaceutical compositions containing the same
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
EA200401114A2 (ru) Замещённые гидроксиэтиламины
DE60140491D1 (de) Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
BG106155A (en) Novel derivatives and analogues of galanthamin
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
BG106847A (bg) Заместени пиперазинови производни като инхибиторина микрозомалния триглицеридпренасящ протеин (mtp)
ATE267816T1 (de) Tan-1057 derivate
DE60318874D1 (en) Pyrazolderivate
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PT871626E (pt) Triazolonas utilizadas como inibidores de sintese da apoliproteina b
RU2007149474A (ru) Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона
EA200970046A1 (ru) Аминопроизводные в-гомоандростанов и в-гетероандростанов